Email this article Effect of cordaron on systolicand diastolic functions of the left ventricle in patients with amixed form of chronic cardiac failure and cardiac arrhythmias
- Authors: Mazur NA1, Sosonkina OV1
-
Affiliations:
- Issue: Vol 78, No 8 (2003)
- Pages: 39-43
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/33364
- ID: 33364
Cite item
Full Text
Abstract
Aim. To study effects of cordaron on central hemodynamics reflecting systolic and diastolic functions
of the left ventricle (LV) in patients with a mixed form of chronic cardiac failure - a systolic dysfunction
and L V diastolic dysfunction type I.
Material and methods. 14 patients with a mixed form of chronic heart failure (CHF) and cardiac arhythmia
were followed up for 6 months. All the patients received ACE inhibitors, diuretics, nitrates
and, additionally, cordaron in a supporting dose 200-300 mg/day. Control of central hemodynamics
was made with echocardiography before, 1, 3 and 6 months of therapy.
Results. For 6 months of therapy LV ejection fraction increased by 16%. LV diastolic function improved,
primarily, due to a rise of the E max (by 52% for 6 months of therapy). This reflected early diastolic filling
of the LV. Improvement of LV diastolic function was associated with heart rate desrease.
Conclusion. Cordaron used in addition to ACE inhibitors, diuretics, nitrates improves both systolic
and diastolic LV function in patients with a mixed form of CHF.
of the left ventricle (LV) in patients with a mixed form of chronic cardiac failure - a systolic dysfunction
and L V diastolic dysfunction type I.
Material and methods. 14 patients with a mixed form of chronic heart failure (CHF) and cardiac arhythmia
were followed up for 6 months. All the patients received ACE inhibitors, diuretics, nitrates
and, additionally, cordaron in a supporting dose 200-300 mg/day. Control of central hemodynamics
was made with echocardiography before, 1, 3 and 6 months of therapy.
Results. For 6 months of therapy LV ejection fraction increased by 16%. LV diastolic function improved,
primarily, due to a rise of the E max (by 52% for 6 months of therapy). This reflected early diastolic filling
of the LV. Improvement of LV diastolic function was associated with heart rate desrease.
Conclusion. Cordaron used in addition to ACE inhibitors, diuretics, nitrates improves both systolic
and diastolic LV function in patients with a mixed form of CHF.
References
- van Veldhuisen К. J., Veld A. J., Dunselman H. J. et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: Results of Dutch Ibopamine Multicenter trial (DIMT). J. Am. Coll. Cardiol. 1993; 22: 1564-1573.
- Uretsky B. F., Young J. B. et al. Randomised study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Result of the PROVED trial. Ibid. 955-962.
- Pasker M., Gheorghiade M., Young J. B. et al. Withdrawal of digoxin from patients chronic heart failure treated with angiotensinconverting enzyme inhibitors. N. Engl. J. Med. 1993; 329: 1-7.
- Digoxin Investigator group. The effect of digoxin on mortality and hospitalizations in patients with heart failure. Presentation at the 45th Annual scientific session American college of cardiology. Orlando, March, 1996.
- CIBIS Investigators and Committees. A randomised trial of pblockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (C1B1S). Circulation 1995; 345: 1756-1763.
- CIBIS II Investiqators and Committees. The Cardiac Insufficiency Bisopropol Study (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13
- Hamer A. W. F., Arcles В., Johns J. A. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J. Am. Coll. Cardiol. 1989; 14: 1768- 1774.
- Burkart F., Pfisterer M., Kiowski W. et al. Effect of antiarrhytmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). Ibid 1990; 16: 1711-1718.
- Pfisterer M., Kiowski W., Buckhardt D. et al. Beneficial effects of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrythmias after myocardial infarction and preserved but not impaired left ventricular function.Am. J. Cardiol. 1992; 69: 1399-1402.
- Navarro-Lopes F., Cosin J., Marrugat J. et al. for the SSSD Investigators. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Ibid 1993; 72: 1243-1248.
- The CASCADE Investigators. Randomised antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). J. Am. Coll. Cardiol. 1993; 22: 280-287.
- Doval H. C., Nul D. R., Grancelli H. O. et al. Randomised trial of low-dose amiodarone in severe congestuve heart failure. Lancet 1994; 344: 493-498.
- Hamer A. W. F., Arcles В., Johns J. A. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J. Am. Coll. Cardiol. 1989; 14: 1768- 1774.
- Singh S. H., Fletcher R. D., Fisher S. G. et al. for the Survival Trial in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arhythmia. N. Engl. J. Med. 1995; 333: 77-82.
- Eichhorn E. J., Bristow M. R. Medical therapy can improve the biological properties of the chronically failing heart a new era in the treatment of heart failure. Circulation 1996. 94 2285- 2296.
- Беленков Ю. Н. Роль нарушений систолы и диастолы в развитии сердечной недостаточности. Тер. арх. 1995; 9: 3-7.
- Pasker M. Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. Circulation 1990; 81(suppl III): I1I78-III86.
- Pasker M., Carver J. R., Rodeheffer R. J. et al. for PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 1991; 325: 1468-1475.
- Hampton J. R., vann Veldhuisen D. J., Kleber F. X. et al. for the Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced heart failure. Lancet 1997; 349: 971-977.
- Pasker M., Narahara K. A., Elkayam U. et al. and the Principal Investigators of the REFLECT Study. Double-blind placebocontrolled study of the efficacy of flosequinan in patients with chronic heart failure. J. Am. Coll. Cardiol. 1993; 22: 65-72.
- Garg R., YusufS. for the Collaborative Group on ACE Inhibitor Trials. Overview of randomised trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure. J. A. M. A. 1995; 273: 1450-1456.
- Lechat P., Pasker M., Chalon S. et al. Clinical effects of p- adrenergic blocade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 1184-1191.
- Канарский С. Г., Скибицкий В. В., Федоров А. В. Диастолическая функция левого желудочка у больных с пароксизмальной фибрилляцией предсердий: влияние профилактической антиаритмической терапии. Кардиология 1998; 10:25-31.
- Сангонова Д. Ф. Желудочковые нарушения ритма сердца и функциональное состояние миокарда у больных с тяжелой сердечной недостаточностью: клинический статус, "качество жизни", прогноз и влияние антиаритмической терапии соталолом, метопрололом и амиодароном: Автореф дисс. . канд. мед наук. М.; 1996.
Supplementary files
